Experiences with

Ropeginterferon alfa-2b

https://www.hematologyadvisor.com/news/polycythemia-vera-ropeginterferon-alfa-2b-dose-regimen-treatment-risk/

https://www.targetedonc.com/view/ropeginterferon-alfa-2b-succeeds-in-phase-3-essential-thrombocythemia-trial

Discussion; The results in our study demonstrate that the new dosing regimen of 250-350-500 µg of ropeginterferon alfa-2b is well-tolerated and highly efficacious in patients suffering from PV.

No specific baseline characteristics among low-risk PV patients appear to be associated with long-term response to ropeginterferon alfa-2b.

They discuss this plot wherein CHR is being lost but VAF still goes down hence "decoupled" and the title "Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa‐2b" The pts were all HU intolerant.

 « The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) have recently been updated to include ropeginterferon alfa-2b-njft, marketed as BESREMi®, as a preferred first-line cytoreductive therapy option for the treatment of adults with symptomatic, low-risk

Saw this on drugshortagescanada and thought it was interesting.... The sole manufacturer of Pegasys® API, Roche Diagnostics GmbH produced a final batch of peginterferon alfa-2a in 2017. Establishment of new API manufacturer for peginterferon alfa-2a, Loba biotech GmbH, Fischamend, Austria (affiliate

Hi everybody, I'm Ciaran & I have been very recently diagnosed Polycythaemia Vera. As you're probably aware, the early stages of research are quite daunting &, whilst my haematologist is recommending Hydroxycarbamide or Peginterferon alfa 2a to rapidly reduce my platelet count & get my high stats under

This potential advantage should be considered when evaluating the individual risk-benefit relationship for ropeginterferon alfa-2b treatment in patients with PV » https://www.nature.com/articles/s41375-023-02008-6

It is to determine the efficacy of using Ropeginterferon alfa-2b-njft for the treatment of Essential Thrombocythemia. It has been approved for use in the treatment of PV, but not ET in the US, as I understand it.

Over a lifetime, the model showed that patients who received ropeginterferon alfa-2b-njft had more years alive (0.4), and higher QALYs (0.4), and higher cost (141,783). What do the results mean?

For the last 60 years I have been a vigilant weight watcher, daily exerciser and have watched my calorie intake. When I commenced treatment for my Essential Thrombocytosis in January 2021, my weight was 53.5kg. Three years later this has ballooned to 60.3kg, despite my efforts to control any

Hola! I'm new to this group and newly diagnosed with essential thrombocythemia. The treatment prescribed is peginterferon alfa-2a. So far I have done one treatment and wow does it suck! I haven't seen anyone else talking about this course of treatment. Is anyone else doing this? I sure could use some

https://www.onclive.com/view/nccn-guidelines-list-ropeginterferon-alfa-2b-as-preferred-treatment-in-polycythemia-vera

My consultant has said I need to start treatment for PV and has asked me to choose between them. I'd really welcome any recommendations. I am new to this site, apologies uf this has been asked before.

https://www.businesswire.com/news/home/20230223005186/en/PharmaEssentia-Initiates-Phase-2b-Trial-of-ropeginterferon-alfa-2b-njft-for-Essential-Thrombocythemia-ET-in-North-America

https://www.businesswire.com/news/home/20230202005200/en/Clinical-Review-of-ropeginterferon-alfa-2b-Suggests-Amended-Dosing-Schedule-May-Support-Improved-Clinical-Outcomes-in-Polycythemia-Vera

alfa-2b not only reduces the number of required phlebotomies but also brings additional significant benefit to the patient by better controlling the target hematocrit, stabilizing the disease and improving patients' quality of life."

My focus is in myeloid malignancies with a research focus in myeloproliferative neoplasms.Graphic: What is ropeginterferon?Dr. Mascarenhas: So, Ropeginterferon is a type of interferon alfa-2b.

can anyone confirm whether Besremi / ropeginterferon-Alfa-2b is approved for first line treatment of Polycythemia Vera on the NHS. im 41, diagnosed 5years ago, fit and healthy but obviously concerned about the long term progression risk.